1. Home
  2. BMM vs ESPR Comparison

BMM vs ESPR Comparison

Compare BMM & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BMM

Blue Moon Metals Inc. Common Shares

N/A

Current Price

$7.19

Market Cap

654.0M

Sector

N/A

ML Signal

N/A

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMM
ESPR
Founded
2007
2008
Country
Canada
United States
Employees
27
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
654.0M
731.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
BMM
ESPR
Price
$7.19
$3.13
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.75
AVG Volume (30 Days)
127.7K
16.8M
Earning Date
05-25-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$3.47
$0.76
52 Week High
$8.63
$4.18

Technical Indicators

Market Signals
Indicator
BMM
ESPR
Relative Strength Index (RSI) 51.55 70.61
Support Level $4.79 $2.37
Resistance Level $8.53 $3.18
Average True Range (ATR) 0.39 0.06
MACD -0.09 0.09
Stochastic Oscillator 35.31 96.01

Price Performance

Historical Comparison
BMM
ESPR

About BMM Blue Moon Metals Inc. Common Shares

Blue Moon Metals Inc is a Canadian exploration stage company which is focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The company also holds the Yava polymetallic project in Nunavut that is in the same volcanic lithologies and south of Glencore's Hackett River deposit. The company is focusing on advancing the Blue Moon and Yava properties.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: